Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
about
Antiplatelet agents for chronic kidney diseaseAntiplatelet agents for chronic kidney diseasePlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesEarly invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent eraAntiplatelet and anticoagulant therapy in elective percutaneous coronary interventionPlatelet glycoprotein IIb/IIIa receptor blockade in coronary artery diseaseEarly and long-term outcome of elective stenting of the infarct-related artery in patients with viability in the infarct-area: Rationale and design of the Viability-guided Angioplasty after acute Myocardial Infarction-trial (The VIAMI-trial)Systematic adjudication of myocardial infarction end-points in an international clinical trialDisagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT studyRoutine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent eraThe role of antiplatelet therapy in the management of acute coronary syndromesClinical use of new antithrombotic therapies for medical management of acute coronary syndromesTherapeutic approaches in arterial thrombosisPharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjectsPotential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplastyPlatelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarctionCommon variations in platelet glycoproteins: pharmacogenomic implicationsUnstable angina and non-ST-segment elevation myocardial infarction: perspectives on combination therapyHeparin and coumadin versus acetylsalicylic acid for prevention of restenosis after coronary angioplastyClinical trials of glycoprotein IIb/IIIa inhibitorsLow molecular weight heparins and glycoprotein IIb/IIIa antagonistsInterventional therapy for coronary artery diseaseClinical implications of CURE and PCI-CURE in patients with the acute coronary syndrome without persistent ST-elevationDifferential benefits and outcomes of tirofiban vs abciximab for acute coronary syndromes in current clinical practicePharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humansCurrent strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromesManagement of antiplatelet therapy for minimization of bleeding risk before cardiac surgeryContemporary management of acute coronary syndromeEvaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitorsAntiplatelet therapy in peripheral occlusive arterial diseasePlatelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of CardiologyEnoxaparin in acute coronary syndromesAnticoagulation in the management of non-ST-segment elevation acute coronary syndrome.Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.Improved clinical outcome after invasive management of patients with recent myocardial infarction and proven myocardial viability: primary results of a randomized controlled trial (VIAMI-trial).Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management.A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results.
P2860
Q24197614-DDE629C0-EA34-448E-B5EF-A93750A95F48Q24200752-14D14227-7B0C-4001-A9A3-4E38F91113C0Q24202522-9C466D22-735F-46B4-9094-0550BDA8CA17Q24202999-C73F5FE0-146C-4129-8867-FB6AAFB4079BQ24235385-819C1421-131C-49C6-A738-F69E134BCF53Q24236794-3EA20FD8-391F-421A-9E02-5F8C884B1D85Q24793199-0742FA68-9C0D-4D96-AFBC-48BE59B471D7Q24793321-367F11CB-3E6E-493B-82A3-AB0394A3AA90Q24800495-BA1416ED-53FA-4EA8-BBB1-4ACBD72F909DQ24805625-546760B7-7808-45E3-A386-129F62FAAE30Q24805692-87BAAA8B-49E4-4D44-8234-F620ED474D9BQ26471900-85297F83-311A-47B6-A1DC-87D9E1319CDCQ28176548-D97AD268-1342-4C6B-9316-2A91F8E0FCFDQ28177271-F2077CF1-E81E-49C9-8415-AE37D738578FQ28187576-A341B0BA-E5DB-4EF6-A339-9ECCFE81FA5DQ28189075-778BFF0B-1F5D-47DA-A6A5-42B67A1127B9Q28190541-C6DB2D48-7BA6-406D-9169-65E79DC99AB7Q28191096-EBBEBDEE-8C11-4FC6-9C8D-C84684796098Q28191774-D1952FC9-8740-4ABB-A258-A8BDFD94E5C6Q28192025-851AAA69-755E-4433-B251-7028AEACFE30Q28192448-646B234F-8ABD-4BD1-892F-AC629CBE9686Q28193162-B6CFD732-65E1-4D01-A5E8-EEA4E1E388D0Q28193196-EBDD19C5-9AE7-43C7-953E-82769A933CCAQ28193761-C5002564-6B8F-4446-9791-507950C72EE5Q28194398-9C2A6A59-7E90-4E39-B3CE-4D13B4BE5FCBQ28195598-8369F7AF-BACA-4F27-9F5C-B2D638687EAAQ28199325-BC5EBE65-A8E9-42F6-8256-D5E84871E232Q28199725-FEE876DA-6ADB-4F0D-8E42-A28ACA155E79Q28201103-6F2202FA-7C4A-482F-88C3-17B4E60C7D23Q28212068-46562FD3-9D81-4100-86A6-80F4ABE1F7CBQ28213564-30F60CDF-89D7-4CDE-8603-C2B6B2272442Q28219001-68080170-1CCE-4762-BBA7-090A61B5EE06Q28219354-F2DD18B9-0D02-47CE-9A93-339AD70FF961Q28239975-F451FA68-B09B-4525-8FE3-2B54BEF3B057Q28301431-0C75BF77-6521-4E17-9E30-3F6CAB5546C0Q30402038-1C96633B-34D5-43F4-966C-8434FDE2EB25Q30438893-84152A83-5C90-4D9E-A5E5-3454875EC261Q30471377-503A04ED-F95F-4FC5-B1A6-13DB3D83CA23Q30658145-6608CD83-C3B2-4A2F-B6EB-42D8A71A0302Q30804000-A53BAF01-9EE1-46D1-9FAA-9BB1BA009719
P2860
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Platelet glycoprotein IIb/IIIa ...... us coronary revascularization.
@en
Platelet glycoprotein IIb/IIIa ...... us coronary revascularization.
@nl
type
label
Platelet glycoprotein IIb/IIIa ...... us coronary revascularization.
@en
Platelet glycoprotein IIb/IIIa ...... us coronary revascularization.
@nl
prefLabel
Platelet glycoprotein IIb/IIIa ...... us coronary revascularization.
@en
Platelet glycoprotein IIb/IIIa ...... us coronary revascularization.
@nl
P1476
Platelet glycoprotein IIb/IIIa ...... us coronary revascularization.
@en
P2093
EPILOG Investigators
P304
P356
10.1056/NEJM199706123362401
P407
P577
1997-06-01T00:00:00Z